First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation
Status:
Recruiting
Trial end date:
2025-10-31
Target enrollment:
Participant gender:
Summary
Furmonertinib, a newly-designed pan-EGFR-TKI with a trifluoroethoxypyridine-based molecule
structure, has shown promising clinical efficacy in EGFR Ex19del/L858R/T790M/Ex20ins mutant
advanced NSCLC with an acceptable safety profile without new signals from 80mg to 240mg dose
level in phase 1-3 clinical trials. Whether EGFR G719X/S768I/L861Q mutation positive advanced
NSCLC patients can benefit from first-line furmonertinib 160mg per day has not been reported.
This study aims to investigate the efficacy and safety of furmonertinib 160mg per day in EGFR
G719X/S768I/L861Q mutant patients under first-line treatment of advanced NSCLC setting.
Phase:
Phase 2
Details
Lead Sponsor:
Chongqing University Cancer Hospital
Collaborators:
Army Specialty Medical Center The Second Affilicated Hospital of Chongqing Medical University